

Hemophilia Treatment Market: Double-Digit Growth Expected to Reach \$26.9 Billion by 2031 | CAGR of 7.5%

WILMINGTON, DELAWARE, UNITED STATES, May 7, 2024 / EINPresswire.com/ -- <u>Hemophilia</u> <u>treatment market</u> size was valued at \$12.8 billion in 2021, and is estimated to reach \$26.9 billion by 2031, growing at a CAGR of 7.5% from 2022 to 2031. Hemophilia is a bleeding disorder that slows the blood clotting process. People with this condition experience prolonged bleeding or oozing following an injury, surgery, or having a tooth pulled. In severe cases of hemophilia,



continuous bleeding occurs after minor trauma or even when there is no obvious injury. Serious complications in the joints, muscles, brain, or other internal organs can result from bleeding. Milder forms of hemophilia do not necessarily involve spontaneous bleeding, and the condition may not become apparent until abnormal bleeding occurs following surgery or a serious injury. The primary treatment for severe hemophilia involves replacing the clotting factor needed through a tube in a vein.

Novo Nordisk A/S, Grifols, S.A, CSL Ltd. (CSL Behring), Pfizer Inc., octapharma ag, Swedish Orphan Biovitrum AB, F. Hoffmann-La Roche AG, Medexus Pharmaceuticals Inc., Bayer AG, Takeda Pharmaceuticals Company Itd

0000000 000000 000000 https://www.alliedmarketresearch.com/request-sample/301

On the basis of type, the hemophilia treatment market is categorized as hemophilia A and hemophilia B. The hemophilia A segment was dominant in 2021 and is expected to remain dominant during the forecast period, owing to the rise in incidence of hemophilia A and increased use of factor VIII. Hemophilia A is also projected to exhibit the fastest market growth during the forecast period, owing to technological advancements in treatment of hemophilia and product approval by regulating authorities.

On the basis of drug therapy, the recombinant coagulation factor concentrates therapy segment was dominant in 2021 and is expected to remain dominant during the forecast period, owing to increase in the number of recombinant technology products available for the treatment. Moreover, non-factor replacement therapy is projected to exhibit the fastest growth during hemophilia treatment market forecast period, owing to increase in target population and rise in R&D activities on the treatment therapies.

Europe was the highest revenue contributor in the 2021 and is expected to continue the same during the forecast period. This was attributed to the research activities for hemophilia treatment, which are soaring in Europe, owing to the well-established healthcare facilities, recent technological advancements, and rise in demand for early diagnosis of hemophilia due to increase in awareness regarding the disease. Asia-Pacific is projected to register the highest CAGR of 8.3% during the forecast period to the hemophilia treatment market share, owing to increase in incidence of population suffering from hemophilia. In addition, increase in healthcare expenditure offers a lucrative opportunity for the hemophilia treatment industry growth.

000 0000000 0000000 https://www.alliedmarketresearch.com/purchase-enquiry/301

- Which are the driving factors responsible for the growth of market?
- Which are the roadblock factors of this market?
- What are the new opportunities, by which market will grow in coming years?
- What are the trends of this market?
- Which are main factors responsible for new product launch?
- How big is the global & regional market in terms of revenue, sales and production?
- How far will the market grow in forecast period in terms of revenue, sales and production?
- Which region is dominating the global market and what are the market shares of each region in the overall market in 2023?
- How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
- Which region has more opportunities?

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

Hemophilia Treatment Market: <u>https://www.alliedmarketresearch.com/hemophilia-treatment-market</u> Artificial Retina Market: <u>https://www.alliedmarketresearch.com/artificial-retina-market-A10878</u> Intrauterine Devices Market: <u>https://www.alliedmarketresearch.com/intrauterine-devices-market-A10999</u> France Ultrasound Guided Infertility Diagnosis and Treatment Market: <u>https://www.alliedmarketresearch.com/france-ultrasound-infertility-diagnosis-and-treatment-market-A15402</u>

0000000:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

0000000000:

David Correa

Portland, OR, United States

USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022,

UK: +44-845-528-1300

Hong Kong: +852-301-84916

India (Pune): +91-20-66346060

Fax: +1(855)550-5975

help@alliedmarketresearch.com

Web: https://www.alliedmarketresearch.com

David Correa Allied Market Research +1 503-894-6022 email us here Visit us on social media: Facebook Twitter LinkedIn Other

This press release can be viewed online at: https://www.einpresswire.com/article/709488260

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2024 Newsmatics Inc. All Right Reserved.